A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy.

Crit Rev Oncol Hematol

Centre for Medication Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.

Published: April 2022

Background: Palifermin, a recombinant keratinocyte growth factor promotes thickening of the mucosa, minimising severity of mucositis caused by chemotherapy and radiotherapy.

Objective: To synthesise published literature on palifermin for the management of oral mucositis, in patients receiving chemotherapy and/or radiotherapy, aiming to ascertain recommendations for practice.

Methods: Databases searched were Medline, Embase, IPA and CIANHL. A meta-analysis included randomised controlled trials (RCT) for palifermin compared to placebo or no palifermin, with the key data extracted being number of events of severe mucositis (defined by WHO criteria grade 3 or 4).

Results: The meta-analysis included 10 RCT. Patients were treated for solid and haematological malignancy. Analysis suggested benefit of palifermin decreasing the incidence of severe mucositis in solid tumours RR0.76 [95%CI 0.63-0.92;p = 0.004], haematological malignancy RR0.63 [95 %CI 0.48-0.82;p = 0.0007] and overall RR0.69 [95 %CI 0.59-0.81;p < 0.0001].

Conclusion: Palifermin reduces the incidence of severe mucositis up to 30 % in patients receiving treatment with chemotherapy and/or radiotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2022.103606DOI Listing

Publication Analysis

Top Keywords

mucositis patients
12
haematological malignancy
12
severe mucositis
12
management oral
8
oral mucositis
8
solid tumours
8
patients receiving
8
chemotherapy and/or
8
and/or radiotherapy
8
meta-analysis included
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!